The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...

A Harvard Business School Healthcare Alumni Association Q&A with Spencer Stuart’s Claudius A. Hildebrand.

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

President Trump’s tariffs will include imported pharmaceuticals, among other items that will impact the industry.

Future development plans include incorporating AI, expanding connectors, and specializing in additional therapeutic areas.

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.

Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.

The survey shows voters, regardless of party affiliation, still support vaccines and are concerned about the reduction in ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

A Harvard Business School Healthcare Alumni Association Q&A with Paul Ollinger, one of Facebook’s first 250 employees.

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.